GeneDx (WGS) - 2024 Q2 - Quarterly Results

Exhibit 99.1 1 Reported second quarter 2024 revenue from continuing operations of $68.9M with 77% year-over-year growth of exome and genome test revenue 2 Narrowed second quarter 2024 adjusted net loss to$ 2.7M GeneDx to host conference call today at 4:30 p.m. ET "Our continued organizational focus on execution fueled our strong second quarter results, giving us confidence to raise full year 2024 revenue guidance to between $255-$ 265 million and reiterate our expectation to reach profitability in the next s ...